These findings suggest that the nonsecosteroidal VDR agonist 34 holds promise as a novel therapeutic candidate for the treatment of osteoporosis in humans, offering a potential alternative to traditional secosteroidal vitamin D analogues [106]. This evidence concerns the gene VDR and osteoporosis.